Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10422211rdf:typepubmed:Citationlld:pubmed
pubmed-article:10422211lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:10422211lifeskim:mentionsumls-concept:C0005795lld:lifeskim
pubmed-article:10422211lifeskim:mentionsumls-concept:C1556084lld:lifeskim
pubmed-article:10422211lifeskim:mentionsumls-concept:C0220908lld:lifeskim
pubmed-article:10422211lifeskim:mentionsumls-concept:C0679199lld:lifeskim
pubmed-article:10422211lifeskim:mentionsumls-concept:C0010174lld:lifeskim
pubmed-article:10422211pubmed:issue3lld:pubmed
pubmed-article:10422211pubmed:dateCreated1999-8-26lld:pubmed
pubmed-article:10422211pubmed:abstractTextThe residual risk of human immunodeficiency virus (HIV) infection from screened blood transfusion was estimated to be 1.7/10(6) between 1993 and 1995 in France. To orient blood safety policies, we have evaluated what would be, from the perspective of blood banks, the best screening strategy in terms of gain in effectiveness and added costs.lld:pubmed
pubmed-article:10422211pubmed:languagefrelld:pubmed
pubmed-article:10422211pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10422211pubmed:citationSubsetIMlld:pubmed
pubmed-article:10422211pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10422211pubmed:statusMEDLINElld:pubmed
pubmed-article:10422211pubmed:monthJunlld:pubmed
pubmed-article:10422211pubmed:issn1246-7820lld:pubmed
pubmed-article:10422211pubmed:authorpubmed-author:SalamonRRlld:pubmed
pubmed-article:10422211pubmed:authorpubmed-author:PerezPPlld:pubmed
pubmed-article:10422211pubmed:authorpubmed-author:SalmiL RLRlld:pubmed
pubmed-article:10422211pubmed:authorpubmed-author:DjossouFFlld:pubmed
pubmed-article:10422211pubmed:authorpubmed-author:Lawson-AyayiS...lld:pubmed
pubmed-article:10422211pubmed:authorpubmed-author:Mathoulin-Pél...lld:pubmed
pubmed-article:10422211pubmed:authorpubmed-author:HuëtCClld:pubmed
pubmed-article:10422211pubmed:issnTypePrintlld:pubmed
pubmed-article:10422211pubmed:volume6lld:pubmed
pubmed-article:10422211pubmed:ownerNLMlld:pubmed
pubmed-article:10422211pubmed:authorsCompleteYlld:pubmed
pubmed-article:10422211pubmed:pagination180-8lld:pubmed
pubmed-article:10422211pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10422211pubmed:meshHeadingpubmed-meshheading:10422211...lld:pubmed
pubmed-article:10422211pubmed:meshHeadingpubmed-meshheading:10422211...lld:pubmed
pubmed-article:10422211pubmed:meshHeadingpubmed-meshheading:10422211...lld:pubmed
pubmed-article:10422211pubmed:meshHeadingpubmed-meshheading:10422211...lld:pubmed
pubmed-article:10422211pubmed:meshHeadingpubmed-meshheading:10422211...lld:pubmed
pubmed-article:10422211pubmed:meshHeadingpubmed-meshheading:10422211...lld:pubmed
pubmed-article:10422211pubmed:meshHeadingpubmed-meshheading:10422211...lld:pubmed
pubmed-article:10422211pubmed:meshHeadingpubmed-meshheading:10422211...lld:pubmed
pubmed-article:10422211pubmed:meshHeadingpubmed-meshheading:10422211...lld:pubmed
pubmed-article:10422211pubmed:meshHeadingpubmed-meshheading:10422211...lld:pubmed
pubmed-article:10422211pubmed:meshHeadingpubmed-meshheading:10422211...lld:pubmed
pubmed-article:10422211pubmed:meshHeadingpubmed-meshheading:10422211...lld:pubmed
pubmed-article:10422211pubmed:meshHeadingpubmed-meshheading:10422211...lld:pubmed
pubmed-article:10422211pubmed:year1999lld:pubmed
pubmed-article:10422211pubmed:articleTitle[Cost-benefit analysis of screening strategies by human immunodeficiency virus in French blood donors].lld:pubmed
pubmed-article:10422211pubmed:affiliationInstitut de santé publique, d'épidémiologie et de développement, université Victor Segalen Bordeaux 2, France.lld:pubmed
pubmed-article:10422211pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10422211pubmed:publicationTypeEnglish Abstractlld:pubmed